Preparing anti-SARS-CoV-2 agent EIDD-2801 by a practical and scalable approach, and quick evaluation

Author: Zhen QIN ¹ ; Bin DONG ² ; Renbing WANG ¹ ; Dechun HUANG ² ; Jubo WANG ¹ ; Xi FENG ¹ ; Jinlei BIAN ¹ ; Zhiyu LI ¹
Author Information

1. Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, China.
2. Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 211100, China.
Publication Type:Journal Article
Keywords: Antiviral drug; Decision tree; EIDD-2801; SARS-CoV-2; Shapley value
From: Acta Pharmaceutica Sinica B 2021;11(11):3678-3682
CountryChina
Language:English
Abstract: EIDD-2801 is an orally bioavailable prodrug, which will be applied for emergency use authorization from the U.S. Food and Drug Administration for the treatment of COVID-19. To investigate the optimal parameters, EIDD-2801 was optimized